Literature DB >> 9829487

The compositional abnormalities of lipoproteins in diabetic renal failure.

P O Attman1, C Knight-Gibson, M Tavella, O Samuelsson, P Alaupovic.   

Abstract

BACKGROUND: Diabetic nephropathy (DN) is a common cause of chronic renal failure (CRF). Patients with DN have abnormal lipoprotein metabolism that can be influenced by both the impairment of renal function and the metabolic control of diabetes. The aim of the study was to explore the specific compositional lipoprotein abnormalities in patients with insulin-dependent DN in comparison with diabetic patients without nephropathy and non-diabetic CRF patients.
METHODS: The lipid and apolipoprotein (apo) composition of major lipoprotein density classes was determined in 20 patients with insulin-dependent diabetes mellitus and nephropathy and compared with that in seven diabetic patients without nephropathy, 20 patients with non-diabetic CRF, and nine healthy control subjects. Lipoproteins isolated by preparative ultracentrifugation were very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL).
RESULTS: Patients with DN had a plasma lipid and apolipoprotein profile characteristic of renal dyslipoproteinaemia with increased concentrations of triglycerides and cholesterol, reduced levels of apoA-I and apoA-II and increased levels of apoB, apoC-II, apoC-III and apoE. These changes were more pronounced in diabetic than in non-diabetic patients with comparable degrees of renal failure. All density classes were characterized by abnormal concentration and composition of some lipid and apolipoprotein constituents. DN patients had a more than four-fold increase of VLDL mass, a three-fold increase of IDL mass, and a significant reduction of HDL mass compared to control subjects. They also had significantly higher concentrations of apoB, apoC-peptides and apoE particularly in VLDL and IDL, and to some extent in LDL. In HDL, DN patients had lower cholesterol, apoA-I, apoA-II and apoC-II levels than controls. The major compositional change in DN patients was a significant increase in the relative content of apoC-peptides in IDL and LDL. The lipoprotein abnormalities were more pronounced in patients with high HbA1c values. In addition, lower GFR and increased proteinuria were associated with higher concentrations of triglycerides and apoC peptides in VLDL, IDL, and LDL in DN patients.
CONCLUSIONS: The results indicate that patients with DN share the characteristic features of dyslipidaemia of CRF with accumulation of intact or partially delipidized apoB-containing lipoproteins enriched in apoC-peptides and apoE, which are present not only in VLDL and IDL but also in LDL density range. The alterations are more marked in DN than in nondiabetic CRF patients reflecting the additional impact of metabolic control. Increased levels of these lipoproteins may represent risk factors for the accelerated development of atherosclerotic vascular disease in these patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829487     DOI: 10.1093/ndt/13.11.2833

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

Review 1.  Dyslipidemia in patients with chronic and end-stage kidney disease.

Authors:  Jad Omran; Ashraf Al-Dadah; Kevin C Dellsperger
Journal:  Cardiorenal Med       Date:  2013-07-13       Impact factor: 2.041

Review 2.  Managing dyslipidemia in chronic kidney disease.

Authors:  Daniel E Weiner; Mark J Sarnak
Journal:  J Gen Intern Med       Date:  2004-10       Impact factor: 5.128

Review 3.  Treatment and impact of dyslipidemia in diabetic nephropathy.

Authors:  Tadashi Toyama; Miho Shimizu; Kengo Furuichi; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2013-11-07       Impact factor: 2.801

4.  Antioxidant Enzymes and Lipid Peroxidation in Type 2 Diabetes Mellitus Patients with and without Nephropathy.

Authors:  Manjulata Kumawat; Tarun Kumar Sharma; Ishwar Singh; Neelima Singh; Veena Singh Ghalaut; Satish Kumar Vardey; Vijay Shankar
Journal:  N Am J Med Sci       Date:  2013-03

5.  Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats.

Authors:  Nora F Banki; Agota Ver; Laszlo J Wagner; Adam Vannay; Peter Degrell; Agnes Prokai; Renata Gellai; Lilla Lenart; Dorottya-Nagy Szakal; Eva Kenesei; Klara Rosta; Gyorgy Reusz; Attila J Szabo; Tivadar Tulassay; Chris Baylis; Andrea Fekete
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

6.  The lipid story in chronic kidney disease: a long story with a happy end?

Authors:  Agata Kujawa-Szewieczek; Andrzej Więcek; Grzegorz Piecha
Journal:  Int Urol Nephrol       Date:  2013-10       Impact factor: 2.370

7.  Lipid Abnormalities in Type 2 Diabetes Mellitus Patients with Overt Nephropathy.

Authors:  Sabitha Palazhy; Vijay Viswanathan
Journal:  Diabetes Metab J       Date:  2017-04       Impact factor: 5.376

8.  Small dense low-density lipoprotein as a potential risk factor of nephropathy in type 2 diabetes mellitus.

Authors:  Essam Abd-Allha; Basma Badr Hassan; Mohamad Abduo; Seham Ahmed Omar; Hamdy Sliem
Journal:  Indian J Endocrinol Metab       Date:  2014-01

9.  Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria.

Authors:  Jennie Lin; Muredach P Reilly; Karen Terembula; F Perry Wilson
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

10.  Dynamic Phenotypes and Molecular Mechanisms to Understand the Pathogenesis of Diabetic Nephropathy in Two Widely Used Animal Models of Type 2 Diabetes Mellitus.

Authors:  Yanfei Liu; Hui Huang; Rui Gao; Yue Liu
Journal:  Front Cell Dev Biol       Date:  2020-03-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.